



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

14.08.2023

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited,  
205(A), 2<sup>nd</sup> Floor, Piramal Agastya Corporate Park,  
Kamani Junction, LBS Road,  
Kurla (West), Mumbai - 400070

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 14<sup>th</sup> August, 2023 - Reg.

\*\*\*

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Monday, 14<sup>th</sup> August, 2023 had inter-alia transacted and approved the following items of business:

1. Approved the unaudited financial results for the quarter ended 30<sup>th</sup> June, 2023.
2. The board recommended the reappointment of Sri. T. Adinarayana, DIN: 00917498 as Non Executive Non Independent director of the company, who retires by rotation and eligible for reappointment subject to the approval of shareholders at the ensuing Annual General Meeting.
3. Sri. PLV Subba Rao, DIN: 07268648, Non Executive Non Independent Director, liable to retire at the ensuing Annual General Meeting has not sought for his reappointment as Director of the Company, hence he will retire/vacate as Director of the company at the ensuing Annual General Meeting.
4. The board recommended the appointment of Sri. China Sai Babu Puppala, DIN: 10275666 as Non Executive Non Independent Director of the company, liable to retire by rotation as recommended by Nomination Remuneration committee, subject to the approval of shareholders at the ensuing 29<sup>th</sup> Annual General Meeting.
5. Approved the Directors report along with the annexures.
6. Approved the Notice of the 29<sup>th</sup> Annual General Meeting and the AGM will be held on Wednesday, the 27<sup>th</sup> day of September, 2023 at 4.00 P.M. through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') and also approved the Annual Report 2022-2023.
7. The Register of Members and Share Transfer Registers will be closed from Thursday, 21<sup>st</sup> September, 2023 to Wednesday, 27<sup>th</sup> September, 2023 (both the days inclusive) and the record date (cut-off date) will be 20<sup>th</sup> September, 2023.



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

We herewith enclose the following:

- A. Un-Audited financial Results along with Limited Review Report for the quarter ended 30<sup>th</sup> June, 2023.
- B. Form A relating to Sri. P.C. Sai Babu, proposed to be appointed as the Director of the Company subject to the approval of members at the ensuing 29<sup>th</sup> Annual General Meeting.

Kindly take the above on your records.

Thanking you,  
Yours faithfully,

For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)  
Company Secretary

Meeting commenced at 04.00 PM.,

Meeting concluded at 05.30 PM.,



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

## Annexure – A

Disclosure of information pursuant to regulation 30 read with clause 7 of para-A, part A of  
Schedule III to the Listing Regulations read with SEBI circular No. CIR/CFD/CMD/4/2015 dated  
September 9, 2015

Sl.No	Particulars	Details
	Reason for change viz. appointment, <del>resignation, removal,</del> death or otherwise	Appointment of Mr. China Sai Babu Puppala, as Non Executive Non Independent Director of the Company liable for retirement by rotation, subject to the approval of members of the Company at the ensuing Annual General Meeting ('AGM').
	Date of appointment/ <del>cessation</del> (as applicable) & term of appointment;	Subject to the consent of the members at the ensuing AGM, appointment of P.C. Sai Babu with effect from 27 <sup>th</sup> September, 2023.
	Brief profile (in case of appointment);	Mr.P.C. Sai Babu, B.Com., FCA., aged about 70 years, is a practicing Chartered Accountant with about 36 years of experience. Earlier ie., from 1978 to 1982 he had worked in AP Civil Supplies Corporation Limited, and from 1982 to 1985 he had worked in AP Construction Corporation Limited and thus he is having varied experience.
	Disclosure of relationships between directors (in case of appointment of a director);	Not Applicable
	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 dated June 20, 2018.	Mr. P.C. Sai Babu, is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

**SIGACHI LABORATORIES LIMITED**

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Unaudited Financial Results For the Quarter ended 30th June, 2023

(Rs. In Lakhs)

Sl.No	Particulars	Quarter ended			Year ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	100.96	31.69	37.21	194.70
2	Other income	9.62	15.46	6.97	50.26
3	Total Income (1+2)	110.58	47.15	44.18	244.96
4	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-
	c) Fair value loss	-	-	39.59	-
	d) Employee benefits expense	9.56	9.44	8.39	35.79
	e) Finance costs	-	-	-	-
	f) Depreciation and amortization expense	5.00	5.02	4.23	18.88
	g) Other expenses	4.19	6.48	3.84	17.05
	Total Expenses	18.75	20.94	56.05	71.72
5	Profit/(Loss) before exceptional items and tax (3-4)	91.83	26.21	(11.87)	173.24
6	Exceptional Items	-	-	-	-
7	Profit/(Loss) before tax (5-6)	91.83	26.21	(11.87)	173.24
8	Tax expense				
	(a) Current tax	6.45	15.20	8.43	46.45
	(b) Deferred tax	9.97	(9.43)	(14.68)	(4.21)
	Total Tax Expense	16.42	5.77	(6.25)	42.24
9	Profit/(Loss) for the Period (7-8)	75.41	20.44	(5.62)	131.00
10	Other Comprehensive income (OCI)				
	(a) Items that will not be reclassified to profit or loss	141.82	(44.38)	(112.99)	(31.97)
	(b) Remeasurement gains / ( losses ) on defined benefit plans	-	0.14	-	0.14
	Tax on Items that will not be reclassified to profit or loss	(14.75)	-	-	-
	( c ) Items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive income	127.07	(44.24)	(112.99)	(31.83)
	Total Comprehensive income (9+10)	202.48	(23.80)	(118.61)	99.17
11	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31
12	Other Equity	-	-	-	2,342.90
13	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.))				
	(1) Basic	1.12	0.30	(0.08)	1.94
	(2) Diluted	1.12	0.30	(0.08)	1.94

Segment wise Revenue, Results and Capital Employed for the Quarter ended 30th June, 2023

(Rs.in Lakhs)

Sl.No	Particulars	Quarter ended			Year ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	<b>Segment Revenue</b>				
	a) Bulk Drugs and Intermediates (Lease Rents)	22.00	44.00	21.00	128.50
	b) Investments	88.58	3.15	(16.42)	116.46
	<b>Total</b>	<b>110.58</b>	<b>47.15</b>	<b>4.58</b>	<b>244.96</b>
	Less: Inter Segment Revenue	-	-	-	-
	<b>Net Sales/Income from Operations</b>	<b>110.58</b>	<b>47.15</b>	<b>4.58</b>	<b>244.96</b>
2	<b>Segment Results Profit/(Loss) before tax and finance Costs from each segment</b>				
	a) Bulk Drugs and Intermediates (Lease Rents)	16.55	37.87	16.26	107.69
	b) Investments	88.58	3.15	(16.42)	116.46
	<b>Total</b>	<b>105.13</b>	<b>41.02</b>	<b>(0.16)</b>	<b>224.15</b>
	Less: (i) Finance Costs	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	13.30	14.81	11.71	50.91
	(iii) Un-allocable income	-	-	-	-
	<b>Total Profit Before Tax</b>	<b>91.83</b>	<b>26.21</b>	<b>(11.87)</b>	<b>173.24</b>
3	<b>Capital Employed</b>				
	(Segment Assets – Segment Liabilities)				
	a) Bulk Drugs and Intermediates	899.91	894.97	657.88	894.97
	b) Investments	2,376.53	2,178.99	2,198.31	2,178.99
	<b>Total</b>	<b>3,276.44</b>	<b>3,073.96</b>	<b>2,856.19</b>	<b>3,073.96</b>

Notes :

- 1 The above Financial results as reviewed and recommended by the Audit Committee are considered and approved by the Board of Directors at their respective meetings held on 14th August, 2023.
- 2 These financial results of the company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 These Financial results have been subjected to limited review by the Statutory Auditors'.
- 4 These Financial Results are available on the Stock Exchange website ([www.msei.in](http://www.msei.in)) and also on the company's website at ([www.sllab.com](http://www.sllab.com)).

for SIGACHI LABORATORIES LIMITED

(T.R.Sekhar)

Executive Director

DN:02943146

Place : Hyderabad

Date : 14.08.2023



**Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Financial Results of M/s SIGACHI LABORATORIES LIMITED pursuant to Regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations 2015, as amended.**

To,

The Board of Directors of **SIGACHI LABORATORIES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of M/s SIGACHI LABORATORIES LIMITED ('The Company') for the quarter ended 30 June 2023. This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements..

**For NSVR & Associates LLP**

Chartered Accountants

FRN: 008801S/S200060

*V. Gangadhara Rao N*

**V Gangadhara Rao N**

Partner

Membership No: 219486

UDIN: 23219486BGQCXC6519

Place: Hyderabad

Date: 14 August 2023



**NSVR & ASSOCIATES LLP**

House No.1-89/1/42, 2nd Floor, Plot No. 41 & 43, Sri Ram Nagar Colony, Kavuri Hills, Guttala Begumpet, Madhapur, Hyderabad, Telangana - 500081. | Ph: 040 - 23391164, E-mail: info@nsvr.in